Solid Biosciences Inc. (SLDB) News & Overview - Discounting Cash Flows
Solid Biosciences Inc.
SLDB (NASDAQ)
Open 4.66
Previous Close 4.6
Volume 1.01 Mil.
Average Volume 1.75 Mil.
Day's Range 4.565 โ€“ 5.03
52 Week Range 2.41-10.37
Market Cap 377.5 Mil.
Moving Average (50) 3.7551
Moving Average (200) 4.63498
Earnings per Share (EPS) -3.01
Price/Earnings (PE) -1.62
Shares Outstanding 77.52 Mil.
Earnings Date Aug 11, 2025
Beta 2.222
Last Dividend 0

SLDB Latest News

SLDB Business Model

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

About Solid Biosciences
Industry Biotechnology
Sector Healthcare
Number of Employees 100
Website & Executive
Website https://www.solidbio.com
CEO (Chief Executive Officer) Alexander G. Cumbo
IPO date 2018-01-26
Contact
Country US
Address 141 Portland Street
City Cambridge
State MA
Phone 617 337 4680
Zip Code 02139
Other Identifiers
CIK 0001707502
ISIN US83422E2046
CUSIP 83422E105
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us